Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke


Phase 2 Results


This study showed that the safety and tolerability of NXY-059 in ICH patients was similar to placebo and well tolerated. There was a mortality rate of 20% in both the NXY-059 and the placebo groups, and no difference in stroke outcomes.